Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women

p21Cip1 and p27Kip1 are cyclin‐dependent kinase inhibitors, which can arrest cell proliferation and serve as tumor suppressors. Reduced protein expression of p21Cip1 and p27Kip1 was frequently observed in a subset of cancers, including breast cancer. In this study, we hypothesized that genetic variants in CDKN1A (encode for p21Cip1) and CDKN1B (encode for p27Kip1) may modulate the risk of breast cancer. To test this hypothesis, we evaluated the associations of the polymorphisms of Ser31Arg and C+20T in CDKN1A and C−79T and Gly109Val in CDKN1B, as well as their combinations, with breast cancer risk in a case‐control study of 368 breast cancer cases and 467 cancer‐free controls in a Chinese population. We found that a significantly increased risk of breast cancer was associated with the variant genotypes of CDKN1B C−79T [adjusted OR = 1.43 (95% CI = 1.03−1.98) for −79TC/TT], compared with the −79CC genotype, but no associations were observed for other variant genotypes. However, the combined variant genotypes of the 4 loci were associated with a significantly increased breast cancer risk (adjusted OR = 1.49, 95% CI = 1.11−2.01 among subjects carrying 3 or more variant alleles), especially among premenopausal women (adjusted OR= 2.30, 95% CI = 1.45−3.66). Furthermore, in premenopausal women, this significant association remained unchanged, after including other individual risk factors in the multivariate logistic regression model, suggesting an independent role of CDKN1A and CDKN1B variants in breast cancer risk. Although the exact biological mechanism remains to be explored, our findings suggest possible involvement of CDKN1A and CDKN1B variants in the etiology of breast cancer. Further large and functional studies are needed to confirm our findings. © 2006 Wiley‐Liss, Inc.

[1]  M. Spitz,et al.  Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. , 2005, Carcinogenesis.

[2]  J. Mester,et al.  p21WAF1/CIP1 Selectively Controls the Transcriptional Activity of Estrogen Receptor α , 2005, Molecular and Cellular Biology.

[3]  M. Hoopmann,et al.  The V109G Polymorphism of the p27 Gene CDKN1B Indicates a Worse Outcome in Node-Negative Breast Cancer Patients , 2004, Tumor Biology.

[4]  M. Spitz,et al.  Association between the V109G Polymorphism of the p27 Gene and the Risk and Progression of Oral Squamous Cell Carcinoma , 2004, Clinical Cancer Research.

[5]  Jianfeng Xu,et al.  A Polymorphism in the CDKN1B Gene Is Associated with Increased Risk of Hereditary Prostate Cancer , 2004, Cancer Research.

[6]  Ming-Tsang Wu,et al.  Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. , 2004, Cancer letters.

[7]  A. Kibel,et al.  CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. , 2003, Cancer research.

[8]  L. Hengst,et al.  ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. , 2002, Genes & development.

[9]  E. Berns,et al.  Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. , 2002, Carcinogenesis.

[10]  M. Wolff,et al.  Waf-1 (p21) and p53 polymorphisms in breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Shu Ye,et al.  PIRA PCR designer for restriction analysis of single nucleotide polymorphisms , 2001, Bioinform..

[12]  R. Miskimins,et al.  Control of Cyclin-Dependent Kinase Inhibitor p27 Expression by Cap-Independent Translation , 2001, Molecular and Cellular Biology.

[13]  N. Park,et al.  Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. , 2001, Cancer letters.

[14]  M. Loda,et al.  Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN , 2000, Molecular and Cellular Biology.

[15]  A. Koff,et al.  A U-Rich Element in the 5′ Untranslated Region Is Necessary for the Translation of p27 mRNA , 2000, Molecular and Cellular Biology.

[16]  M. Pagano,et al.  Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.

[17]  G. Pruneri,et al.  Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Kemp,et al.  Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis , 1999, Oncogene.

[19]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[20]  J. Kato,et al.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 , 1999, Nature.

[21]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[22]  K. Kato,et al.  WAF1 genotype and endometrial cancer susceptibility. , 1999, Gynecologic oncology.

[23]  L. Klotz,et al.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. , 1998, Cancer research.

[24]  Z. Shao,et al.  p21/waf1/cip1 and mdm‐2 expression in breast carcinoma patients as related to prognosis , 1997, International journal of cancer.

[25]  K. Mimori,et al.  p27 expression and gastric carcinoma , 1997, Nature Medicine.

[26]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[27]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[28]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[29]  S. Groshen,et al.  WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. , 1997, The American journal of pathology.

[30]  G. Karpati.  Utrophin muscles in on the action , 1997, Nature Medicine.

[31]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[32]  A. Berchuck,et al.  Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines , 1996, Molecular carcinogenesis.

[33]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[34]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[35]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[36]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[37]  P. D. Lee,et al.  Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. , 1995, Human molecular genetics.

[38]  C. Bartram,et al.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. , 1995, Cancer research.

[39]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[40]  H. Cavé,et al.  Identification of a polymorphism in the coding region of the p27Kip1 gene. , 1995, Annales de genetique.

[41]  B. Vogelstein,et al.  Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.

[42]  D. Givol,et al.  A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. , 1994, Oncogene.

[43]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[44]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[45]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.